Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Crossref DOI link: https://doi.org/10.1186/s13045-016-0332-8
Published Online: 2016-10-04
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sun, Yongkun
Niu, Wei
Du, Feng
Du, Chunxia
Li, Shuting
Wang, Jinwan
Li, Li
Wang, Fengqing
Hao, Yu
Li, Chuan
Chi, Yihebali